High expression of biglycan is associated with poor prognosis in patients with esophageal squamous cell carcinoma

International Journal of Clinical and Experimental Pathology

Volumn 6, Issue 11, 2013, Pages 2497-2505

  Zhu, Ying Hui ^a   Yang, Fu ^a   Zhang, Shui Shen ^a   Zeng, Ting Ting ^a   Xie, Xuan ^a   Guan, Xin Yuan ^a,b  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

BGN; ESCC; Prognosis

Indexed keywords

BGN PROTEIN, HUMAN; BIGLYCAN; MESSENGER RNA; TUMOR MARKER;

ADULT; AGED; ARTICLE; BGN; CANCER STAGING; CHEMISTRY; CHI SQUARE DISTRIBUTION; ESCC; ESOPHAGUS TUMOR; FEMALE; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MALE; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; REAL TIME POLYMERASE CHAIN REACTION; RISK FACTOR; SQUAMOUS CELL CARCINOMA; TIME; TISSUE MICROARRAY; TUMOR INVASION; UPREGULATION; VERY ELDERLY;

BGN; ESCC; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; BIGLYCAN; CARCINOMA, SQUAMOUS CELL; CHI-SQUARE DISTRIBUTION; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; REAL-TIME POLYMERASE CHAIN REACTION; RISK FACTORS; RNA, MESSENGER; TIME FACTORS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84887125746     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Kamangar F, Dores GM and Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents:defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006;24:2137-2150.
2. Wheeler JB and Reed CE. Epidemiology of esophageal cancer. Surg Clin North Am 2012;92:1077-1087.
3. Hongo M, Nagasaki Y and Shoji T. Epidemiology of esophageal cancer:Orient to Occident. Effects of chronology, geography and ethnicity. J Gastroenterol Hepatol 2009;24:729-735.
4. Stoner GD and Gupta A. Etiology and chemoprevention of esophageal squamous cell carcinoma. Carcinogenesis 2001;22:1737-1746.
5. Xiao ZF, Yang ZY, Liang J, Miao YJ, Wang M, Yin WB, Gu XZ, Zhang DC, Zhang RG and Wang LJ. Value of radiotherapy after radical surgery for esophageal carcinoma:a report of 495 patients. Ann Thorac Surg 2003;75:331-336.
6. Shimizu K, Hihara J, Yoshida K and Toge T. Clinical evaluation of low-dose cisplatin and 5-fluorouracil as adjuvant chemoradiotherapy for advanced squamous cell carcinoma of the esophagus. Hiroshima J Med Sci 2005;54:67-71.
7. Hagymasi K and Tulassay Z. [Risk factors for esophageal cancer, and possible genetic background]. Orv Hetil 2009;150:407-413.
8. Ullah M, Sittinger M and Ringe J. Extracellular matrix of adipogenically differentiated mesenchymal stem cells reveals a network of collagen filaments, mostly interwoven by hexagonal structural units. Matrix Biol 2013;[Epub ahead of print].
9. Schaefer L and Iozzo RV. Biological functions of the small leucine-rich proteoglycans:from genetics to signal transduction. J Biol Chem 2008;283:21305-21309.
10. Gotte M, Sofeu Feugaing DD and Kresse H. Biglycan is internalized via a chlorpromazine-sensitive route. Cell Mol Biol Lett 2004;9:475-481.
11. Wadhwa S, Embree MC, Bi Y and Young MF. Regulation, regulatory activities, and function of biglycan. Crit Rev Eukaryot Gene Expr 2004;14:301-315.
12. Kinsella MG, Bressler SL and Wight TN. The regulated synthesis of versican, decorin, and biglycan:extracellular matrix proteoglycans that influence cellular phenotype. Crit Rev Eukaryot Gene Expr 2004;14:203-234.
13. Tufvesson E and Westergren-Thorsson G. Biglycan and decorin induce morphological and cytoskeletal changes involving signalling by the small GTPases RhoA and Rac1 resulting in lung fibroblast migration. J Cell Sci 2003;116:4857-4864.
14. Groth S, Schulze M, Kalthoff H, Fandrich F and Ungefroren H. Adhesion and Rac1-dependent regulation of biglycan gene expression by transforming growth factor-beta. Evidence for oxidative signaling through NADPH oxidase. J Biol Chem 2005;280:33190-33199.
15. Gu X, Ma Y, Xiao J, Zheng H, Song C, Gong Y and Xing X. Up-regulated biglycan expression correlates with the malignancy in human colorectal cancers. Clin Exp Med 2012;12:195-199.
16. Mikula M, Rubel T, Karczmarski J, Goryca K, Dadlez M and Ostrowski J. Integrating proteomic and transcriptomic high-throughput surveys for search of new biomarkers of colon tumors. Funct Integr Genomics 2010;[Epub ahead of print].
17. Pan S, Cheng L, White JT, Lu W, Utleg AG, Yan X, Urban ND, Drescher CW, Hood L and Lin B. Quantitative proteomics analysis integrated with microarray data reveals that extracellular matrix proteins, catenins, and p53 binding protein 1 are important for chemotherapy response in ovarian cancers. OMICS 2009;13:345-354.
18. Nishino R, Honda M, Yamashita T, Takatori H, Minato H, Zen Y, Sasaki M, Takamura H, Horimoto K, Ohta T, Nakanuma Y and Kaneko S. Identification of novel candidate tumour marker genes for intrahepatic cholangiocarcinoma. J Hepatol 2008;49:207-216.
19. Weber CK, Sommer G, Michl P, Fensterer H, Weimer M, Gansauge F, Leder G, Adler G and Gress TM. Biglycan is overexpressed in pancreatic cancer and induces G1-arrest in pancreatic cancer cell lines. Gastroenterology 2001;121:657-667.
20. Modolo F, Biz MT, Martins MT, Machado de Sousa SO and de Araujo NS. Expression of extracellular matrix proteins in adenomatoid odontogenic tumor. J Oral Pathol Med 2010;39:230-235.
21. Xie D, Sham JS, Zeng WF, Lin HL, Che LH, Wu HX, Wen JM, Fang Y, Hu L and Guan XY. Heterogeneous expression and association of beta-catenin, p16 and c-myc in multistage colorectal tumorigenesis and progression detected by tissue microarray. Int J Cancer 2003;107:896-902.
22. Brown RS and Wahl RL. Overexpression of Glut-1 glucose transporter in human breast cancer. An immunohistochemical study. Cancer 1993;72:2979-2985.
23. Rice TW, Blackstone EH and Rusch VW. 7th edition of the AJCC Cancer Staging Manual:esophagus and esophagogastric junction. Ann Surg Oncol 2010;17:1721-1724.
24. Iozzo RV and Schaefer L. Proteoglycans in health and disease:novel regulatory signaling mechanisms evoked by the small leucine-rich proteoglycans. FEBS J 2010;277:3864-3875.
25. Galamb O, Sipos F, Spisak S, Galamb B, Krenacs T, Valcz G, Tulassay Z and Molnar B. Potential biomarkers of colorectal adenoma-dysplasia-carcinoma progression:mRNA expres-sion profiling and in situ protein detection on TMAs reveal 15 sequentially upregulated and 2 downregulated genes. Cell Oncol 2009;31:19-29.
26. Shimizu-Hirota R, Sasamura H, Kuroda M, Kobayashi E, Hayashi M and Saruta T. Extracellular matrix glycoprotein biglycan enhances vascular smooth muscle cell proliferation and migration. Circ Res 2004;94:1067-1074.
27. Berendsen AD, Fisher LW, Kilts TM, Owens RT, Robey PG, Gutkind JS and Young MF. Modulation of canonical Wnt signaling by the extracellular matrix component biglycan. Proc Natl Acad Sci USA 2011;108:17022-17027.
28. Schaefer L, Beck KF, Raslik I, Walpen S, Mihalik D, Micegova M, Macakova K, Schonherr E, Seidler DG, Varga G, Schaefer RM, Kresse H and Pfeilschifter J. Biglycan, a nitric oxide-regulated gene, affects adhesion, growth, and survival of mesangial cells. J Biol Chem 2003;278:26227-26237.
29. Wong FH, Huang CY, Su LJ, Wu YC, Lin YS, Hsia JY, Tsai HT, Lee SA, Lin CH, Tzeng CH, Chen PM, Chen YJ, Liang SC, Lai JM and Yen CC. Combination of microarray profiling and protein-protein interaction databases delineates the minimal discriminators as a metastasis network for esophageal squamous cell carcinoma. Int J Oncol 2009;34:117-128.
30. Wight TN. Cell biology of arterial proteoglycans. Arteriosclerosis 1989;9:1-20.
31. Ruoslahti E and Yamaguchi Y. Proteoglycans as modulators of growth factor activities. Cell 1991;64:867-869.
32. Bereczki E, Gonda S, Csont T, Korpos E, Zvara A, Ferdinandy P and Santha M. Overexpression of biglycan in the heart of transgenic mice:an antibody microarray study. J Proteome Res 2007;6:854-861.
33. Yamamoto K, Ohga N, Hida Y, Maishi N, Kawamoto T, Kitayama K, Akiyama K, Osawa T, Kondoh M, Matsuda K, Onodera Y, Fujie M, Kaga K, Hirano S, Shinohara N, Shindoh M and Hida K. Biglycan is a specific marker and an autocrine angiogenic factor of tumour endothelial cells. Br J Cancer 2012;106:1214-1223.
34. Lee J, Lee KE, Im YH, Kang WK, Park K, Kim K and Shim YM. Adjuvant chemotherapy with 5-fluorouracil and cisplatin in lymph node-positive thoracic esophageal squamous cell carcinoma. Ann Thorac Surg 2005;80:1170-1175.
35. Ando N, Iizuka T, Ide H, Ishida K, Shinoda M, Nishimaki T, Takiyama W, Watanabe H, Isono K, Aoyama N, Makuuchi H, Tanaka O, Yamana H, Ikeuchi S, Kabuto T, Nagai K, Shimada Y, Kinjo Y, Fukuda H;Japan Clinical Oncology Group. Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus:a Japan Clinical Oncology Group Study--JCOG9204. J Clin Oncol 2003;21:4592-4596.
36. Tepper J, Krasna MJ, Niedzwiecki D, Hollis D, Reed CE, Goldberg R, Kiel K, Willett C, Sugarbaker D and Mayer R. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer:CALGB 9781. J Clin Oncol 2008;26:1086-1092.
37. Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J;Australasian Gastro-Intestinal Trials Group. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma:a meta-analysis. Lancet Oncol 2007;8:226-234.
38. Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RJ, Barbour A, Gebski V;Australasian Gastro-Intestinal Trials Group. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma:an updated meta-analysis. Lancet Oncol 2011;12:681-692.
39. Burmeister BH, Smithers BM, Gebski V, Fitzgerald L, Simes RJ, Devitt P, Ackland S, Gotley DC, Joseph D, Millar J, North J, Walpole ET, Denham JW;Trans-Tasman Radiation Oncology Group;Australasian Gastro-Intestinal Trials Group. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus:a randomised controlled phase III trial. Lancet Oncol 2005;6:659-668.
40. van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, Richel DJ, Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, Cuesta MA, Blaisse RJ, Busch OR, ten Kate FJ, Creemers GJ, Punt CJ, Plukker JT, Verheul HM, Spillenaar Bilgen EJ, van Dekken H, van der Sangen MJ, Rozema T, Biermann K, Beukema JC, Piet AH, van Rij CM, Reinders JG, Tilanus HW, van der Gaast A;CROSS Group. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012;366:2074-2084.